These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1471673)

  • 21. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet sensitivity to prostacyclin in pregnancy and uterine cancer.
    Briel RC; Lippert TH
    Eur J Obstet Gynecol Reprod Biol; 1981 Jun; 12(1):19-23. PubMed ID: 7018952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
    Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelets from patients on haemodialysis show impaired responses to nitric oxide.
    Gordge MP; Neild GH
    Clin Sci (Lond); 1992 Sep; 83(3):313-8. PubMed ID: 1327648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome.
    Wilson AP; Efthimiou J; Betteridge DJ
    Eur J Clin Invest; 1988 Aug; 18(4):410-4. PubMed ID: 2971547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet sensitivity to prostacyclin in diabetes mellitus.
    Pillay PK; Pillay U; Balasubramaniam P; Lee KO
    Ann Acad Med Singap; 1985 Apr; 14(2):229-31. PubMed ID: 3898978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ticlopidine of platelet function in men with stable angina pectoris.
    Berglund U; von Schenck H; Wallentin L
    Thromb Haemost; 1985 Dec; 54(4):808-12. PubMed ID: 3911481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of human platelet functions by verapamil.
    Ikeda Y; Kikuchi M; Toyama K; Watanabe K; Ando Y
    Thromb Haemost; 1981 Apr; 45(2):158-61. PubMed ID: 6789494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E1 at clinically relevant concentrations inhibits aggregation of platelets under synergic interaction with endothelial cells.
    Koga T; Az-ma T; Yuge O
    Acta Anaesthesiol Scand; 2002 Sep; 46(8):987-93. PubMed ID: 12190800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide donors inhibit platelet spreading on surfaces coated with fibrinogen but not with fibronectin.
    Shahbazi T; Jones N; Radomski MW; Moro MA; Gingell D
    Thromb Res; 1994 Sep; 75(6):631-42. PubMed ID: 7831682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis.
    Chirkov YY; Mishra K; Chandy S; Holmes AS; Kanna R; Horowitz JD
    J Heart Valve Dis; 2006 Jan; 15(1):28-33. PubMed ID: 16480009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil.
    Berkels R; Klotz T; Sticht G; Englemann U; Klaus W
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):413-21. PubMed ID: 11300654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
    Sogo N; Magid KS; Shaw CA; Webb DJ; Megson IL
    Biochem Biophys Res Commun; 2000 Dec; 279(2):412-9. PubMed ID: 11118301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin.
    Macdonald PS; Read MA; Dusting GJ
    Thromb Res; 1988 Mar; 49(5):437-49. PubMed ID: 3287674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic actions of prostacyclin and an isoquinoline derivative (CH-102) on ADP-induced aggregation of dog platelets in vitro.
    Pataricza J; Bor P; Szekeres L
    Biomed Biochim Acta; 1984; 43(12):1365-9. PubMed ID: 6398698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative insensitivity of epinephrine induced platelet aggregation to prostacyclin.
    Zahavi M; Zahavi J
    Thromb Res; 1986 Oct; 44(1):119-24. PubMed ID: 3538494
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells.
    Kosonen O; Kankaanranta H; Malo-Ranta U; Ristimäki A; Moilanen E
    Br J Pharmacol; 1998 Sep; 125(2):247-54. PubMed ID: 9786495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of low concentrations of prostacyclin on platelet function in vitro.
    van Heerden PV; Gibbs NM; Michalopoulos N
    Anaesth Intensive Care; 1997 Aug; 25(4):343-6. PubMed ID: 9288373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.